6 results about "Precocious puberty" patented technology

The invention relates to the technical field of molecular markers, and discloses an SNP molecular marker related to chicken premature traits and application of the SNP molecular marker in breeding, the SNP molecular marker related to chicken premature traits is a single nucleotide polymorphism site in a chicken CHADL gene and comprises a site 1, a site 2, a site 3, a site 4, a site 5, a site 6, a site 7, a site 7, a site 7, a site 7, a site 8, a site 7, a site 8, a site 7, a site 8, a site 7, and a site 7, the site 2 is located at the site g.49793806 of the chromosome 1, and the base variation is C / T; the site 3 is located at the site g.49794002 of the chromosome 1, and the base variation is C / T; the site 4 is located at the site g.49794431 of the chromosome 1, and the base variation is C / T; the site 5 is located at the site g.49794441 of the chromosome 1, and the base variation is A / G; the site 6 is located at the site g.49795003 of the chromosome 1, and the base variation is C / T; the site 7 is located at the site g.49797766 of the chromosome 1, and the base variation is A / G; the site 8 is located at the site g.49798159 of the chromosome 1, and the base variation is T / G. The SNP molecular marker can accurately show chicken prematurity related traits.

FIELD: pediatrics; endocrinology.SUBSTANCE: invention can be used to predict the development of idiopathic precocious development (IPD) in obese girls under 9 years of age. The method includes determining the patient's height and BMI. Then, bioimpedance analysis is performed and the basal metabolic rate (BM), percentage of adipose tissue, active cellular mass (ACM) and skeletal muscle mass (SMM), and the proportion of SMM are determined. In addition, X-rays of the hands are performed and bone age is determined using the Greulich atlas. Furthermore, with normal values of BM, percentage of body fat and ACM, elevated values of BMI, SMM, proportion of SMM, the presence of tall stature and bone age ahead of biological age by 1-3 years, the development of IPD is predicted in girls with obesity up to 9 years of age.EFFECT: method is simple, accessible, and allows for the effective prediction of the development of IPD in obese girls.1 cl, 2 ex

The invention discloses a traditional Chinese medicine composition for treating child development retardation and bone age abnormity and application thereof, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition comprises the following raw materials by weight: 8-20 parts of radix fici simplicissimae, 4-15 parts of bighead atractylodes rhizome, 4-12 parts of radix clematidis, 8-18 parts of Chinese angelica, 5-16 parts of teasel root, and 5-16 parts of white peony root; the invention further discloses a preparation method and application of the traditional Chinese medicine composition. According to the invention, through three-dimensional linkage of tonifying spleen and kidney to consolidate foundation and fire, nourishing qi and blood to charge sources and dredging meridians and collaterals to improve efficiency, the core targets of inhibiting abnormal bone age progression, promoting growth and strengthening muscles and bones are achieved. Wherein the radix clematidis has the characteristics of dredging meridians and removing bone sticking and can assist in regulating bone metabolism and dredging the drug efficacy path. The composition has the effect of clinically inhibiting the bone age abnormal progress caused by precocious puberty, and becomes a characteristic synergistic key for treating the dwarf disease and inhibiting the bone age abnormal progress. The whole formula gives consideration to inhibition of pathological bone age development and excitation of physiological growth potential, and a traditional Chinese medicine solution for treating both symptoms and root causes is provided for children with growth and development disorders.

Disclosed are compositions and methods including Anti-Müllerian Hormone (AMH) receptor binding peptides. The AMH receptor binding peptides can be used, for example, to modify the activity of the AMH receptor. For example, the AMH receptor binding peptides can activate the AMH receptor, such as the AMH receptor 2, thereby mimicking the function of AMH. In other examples, the AMH receptor binding peptides function as AMH receptor antagonists, thereby interfering with the function of endogenous AMH. By modifying the activity of the AMH receptor, the peptides have multiple applications, including for example modification of treatment of precocious puberty in females, delay of natural menopause, preservation of ovarian follicular reserve, contraception, fertility preservation after ovarian cortex transplant, treatment of endometriosis, treatment of cancer and / or cancer prevention, and treatment of polycystic ovary syndrome (PCOS).

The invention discloses a male-source female peripheral precocious precocious intervention target based on an imprinting gene Gnas and application of the male-source female peripheral precocious precocious intervention target. The pregestation caffeine exposure of the male parent has obvious influence on the ovarian generation of the female offspring, and can lead to PPP (Poly-Protein Protein) generation. Through screening and verification, it is found that expression increase of the ovarian granular cell imprinting gene Gnas plays a key role in the parent PPP. The cAMP / PKA / CREB signaling pathway can be up-regulated or down-regulated by overexpression of the ovary Gnas of the female rat or knockout of the ovary Gnas of the female offspring based on a parent PPP model, so that the ovary estrogen synthesis function and PPP generation are induced or inhibited. The invention discloses a key effect of the Gnaas / cAMP / PKA / CREB pathway in regulation and control of ovarian estrogen synthesis, and provides a new biological basis and an early prevention and treatment strategy for targeted therapy of female PPP.

The invention discloses application of aucubin in treatment of sexual precocity. According to the application, a precocious puberty mouse model is firstly constructed, in a Balb / c mouse precocious puberty model induced by a low dose of BPA, aucubin intervention can significantly down-regulate expression of key genes KISS1 and GnRH1 in hypothalamic development regulation and central development regulation, reduce the level of sex hormone in peripheral blood, delay ovarian development, and inhibit hypothalamic development regulation and central development regulation. The vaginal opening time (body surface marks of rodent model sexual development initiation) is delayed, so that sexual precocious puberty is treated. The invention provides a new medicine scheme for treating precocious puberty, provides a new thought for research and development of precocious puberty treatment medicines, and expands the application range of aucubin.